The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

Esperion has settled patent litigation with Dr. Reddy's Laboratories, agreeing that generic versions of NEXLETOL and NEXLIZET will not be marketed in the US before April 19, 2040.

Alvotech, a global biotech company specializing in biosimilar medicines, will release its financial results for the first half of 2025 on August 14, 2025, via a webcast and conference call.

The global paracetamol market is projected to grow from USD 876.48 Million in 2024 to USD 1460.23 Million by 2034, with a steady 5.24% CAGR, driven by increasing healthcare awareness and rising incidences of chronic conditions.

Global fibromyalgia treatment market is expanding with novel drug developments, digital health tools, and personalized medicine approaches, driven by increasing awareness and technological innovations in pain management.

A market research study reveals the global Lenacapavir Injection market is expected to grow to USD 5.68 Billion by 2034, with a 5.1% CAGR, driven by long-acting HIV treatment demand and innovations in injectable formulations.

The functional dyspepsia market is experiencing growth through innovative pharmacological treatments, digital health solutions, and emerging therapies, with North America leading market development and significant potential in Asia-Pacific.

The global burn pain market is experiencing rapid expansion driven by increasing burn incidences, advancements in pain management technologies, and innovative therapies addressing complex burn pain challenges.

Alvotech and Dr. Reddy's have entered into a collaboration to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets.

Alvotech, a biotech company, has entered into a collaboration with Dr. Reddy's Laboratories, an Indian pharmaceutical company, to co-develop a biosimilar version of the cancer drug Keytruda. The collaboration aims to reduce development and manufacturing costs, shorten the development timeline, and accelerate global market access for the biosimilar.